Iven-Alex von Mücke-Heim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iven-Alex von Mücke-Heim has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Angelika Erhardt
Psychiatry Department, Clinical Anxiety Research, University of Würzburg, Würzburg, Germany
5 shared publications- Jan Michael Deussing
Molecular Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany
5 shared publications Evangelos Kokolakis
Department Clinical Translation, Max Planck Institute of Psychiatry (MPIP), Munich, Germany
3 shared publicationsJan M. Deussing
Research Group Molecular Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany
3 shared publicationsSarah Kläffgen
Max Planck Institute of Psychiatry, Molecular Neurogenetics, Kraepelinstraße 2-10, 80804, Munich, Germany
3 shared publicationsClemens Ries
Max Planck Institute of Psychiatry, Molecular Neurogenetics, Munich, Germany
2 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 8149
Protocol of the randomized double blind sham controlled AddVNS study of transcutaneous vagus nerve stimulation mechanisms in depression
Depression is among the most prevalent mental disorders worldwide, carrying one of the highest burden of disease among all mental disorders. While invasive vagus nerve stimulation has been approved for treatment-resistant depression for decades, its clinical use is limited by surgical risks and heterogeneous clinical efficacy. Transcutaneous auricular VNS (tVNS) may offer a non-invasive alternative, but to date it remains experimental due to limited high-quality evidence, unclear biological mechanisms of action, and rudimentary knowledge on optimal stimulation parameters. To address these gaps, we initiated the AddVNS study. The AddVNS study ( Add -on t VNS in depression) is a monocentric, exploratory, prospective, randomized, double-blind, sham-controlled interventional trial conducted at the Max Planck Institute of Psychiatry’s research hospital. Adult patients with a depressive episode (ICD-10: F31–33) were assigned to receive active or sham transcutaneous vagus nerve stimulation (tVNS) in addition to treatment-as-usual (TAU) over a six-week period. Stimulation is administered three times daily (30 to 60 min each), five days per week. A deep phenotyping strategy is applied, including repeated psychophysiological measures (e.g., pupillometry, ECG, photoplethysmography, electrogastrogram) and neuroimaging (structural and functional MRI) at baseline and post-intervention, continuous actigraphy, repeated blood and stool sample acquisition (pre-, mid-, and post-intervention) for multiomic investigation, comprehensive neuropsychology including self-rated personality assessment, and closely monitored clinical evaluations. The patient-reported outcomes are collected weekly, the clinician-rated scales pre-, mid-, and post-intervention. In addition, follow-up self-ratings are obtained at 6 and 12 weeks post-tVNS. The main objective of AddVNS is to improve our understanding of the biological effects elicited by tVNS in depression. By combining rigorous methodology with an extensive and longitudinal multimodal approach, AddVNS represents the most comprehensive investigation of tVNS effects and markers in depression to date. We believe it to significantly advance our mechanistic understanding and subsequently clinical translation of this promising intervention.
- 2 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 8149
Open AccessProtocol of the randomized double blind sham controlled AddVNS study of transcutaneous vagus nerve stimulation mechanisms in depression
Depression is among the most prevalent mental disorders worldwide, carrying one of the highest burden of disease among all mental disorders. While invasive vagus nerve stimulation has been approved for treatment-resistant depression for decades, its clinical use is limited by surgical risks and heterogeneous clinical efficacy. Transcutaneous auricular VNS (tVNS) may offer a non-invasive alternative, but to date it remains experimental due to limited high-quality evidence, unclear biological mechanisms of action, and rudimentary knowledge on optimal stimulation parameters. To address these gaps, we initiated the AddVNS study. The AddVNS study ( Add -on t VNS in depression) is a monocentric, exploratory, prospective, randomized, double-blind, sham-controlled interventional trial conducted at the Max Planck Institute of Psychiatry’s research hospital. Adult patients with a depressive episode (ICD-10: F31–33) were assigned to receive active or sham transcutaneous vagus nerve stimulation (tVNS) in addition to treatment-as-usual (TAU) over a six-week period. Stimulation is administered three times daily (30 to 60 min each), five days per week. A deep phenotyping strategy is applied, including repeated psychophysiological measures (e.g., pupillometry, ECG, photoplethysmography, electrogastrogram) and neuroimaging (structural and functional MRI) at baseline and post-intervention, continuous actigraphy, repeated blood and stool sample acquisition (pre-, mid-, and post-intervention) for multiomic investigation, comprehensive neuropsychology including self-rated personality assessment, and closely monitored clinical evaluations. The patient-reported outcomes are collected weekly, the clinician-rated scales pre-, mid-, and post-intervention. In addition, follow-up self-ratings are obtained at 6 and 12 weeks post-tVNS. The main objective of AddVNS is to improve our understanding of the biological effects elicited by tVNS in depression. By combining rigorous methodology with an extensive and longitudinal multimodal approach, AddVNS represents the most comprehensive investigation of tVNS effects and markers in depression to date. We believe it to significantly advance our mechanistic understanding and subsequently clinical translation of this promising intervention.
- Top Cited PapersOpen Access
- 10 February 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Clinical and biological markers of electroconvulsive therapy effectiveness: a narrative review
Electroconvulsive therapy (ECT) is the most effective treatment for several particularly severe or pharmacotherapy-resistant psychiatric disorders, and a growing number of studies have investigated factors influencing the effectiveness of ECT. The objective of this article is to review the current evidence on clinical and biological markers potentially related to response to ECT and to outline perspectives for future research. In depressive disorders, the presence of clinical characteristics such as higher age, psychotic and psychomotor symptoms, and the absence of comorbid personality disorders are associated with a particularly good response to ECT. However, these clinical factors alone explain only a part of the variance of treatment outcome. Biomarkers at the genetic/epigenetic, immune inflammatory, and brain imaging levels are now providing promising and, in part, converging findings on both the mechanism of action and predictors of response to ECT. Taken together, these findings suggest a close relationship between specific clinical symptoms, the immune inflammatory, and neuroplastic mechanisms of ECT. While genetic studies consistently indicate a higher genetic risk load in patients referred for ECT, findings regarding the predictive value of polygenic risk scores and also epigenetic markers for ECT response remain inconsistent. In the future, combining clinical features and biomarkers could help define subgroups of psychiatric disorders with distinct pathophysiology and reliably predict treatment outcomes at the individual patient level. For now, it may be assumed that different and possibly age-dependent prototypical forms of depressive disorders exist, which are characterized by specific clinical (psychotic and psychomotor symptoms) and inflammatory markers (higher levels of IL-6 and CRP) and show a differential response to treatment modalities.
- 10 February 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Top Cited PapersOpen AccessClinical and biological markers of electroconvulsive therapy effectiveness: a narrative review
Electroconvulsive therapy (ECT) is the most effective treatment for several particularly severe or pharmacotherapy-resistant psychiatric disorders, and a growing number of studies have investigated factors influencing the effectiveness of ECT. The objective of this article is to review the current evidence on clinical and biological markers potentially related to response to ECT and to outline perspectives for future research. In depressive disorders, the presence of clinical characteristics such as higher age, psychotic and psychomotor symptoms, and the absence of comorbid personality disorders are associated with a particularly good response to ECT. However, these clinical factors alone explain only a part of the variance of treatment outcome. Biomarkers at the genetic/epigenetic, immune inflammatory, and brain imaging levels are now providing promising and, in part, converging findings on both the mechanism of action and predictors of response to ECT. Taken together, these findings suggest a close relationship between specific clinical symptoms, the immune inflammatory, and neuroplastic mechanisms of ECT. While genetic studies consistently indicate a higher genetic risk load in patients referred for ECT, findings regarding the predictive value of polygenic risk scores and also epigenetic markers for ECT response remain inconsistent. In the future, combining clinical features and biomarkers could help define subgroups of psychiatric disorders with distinct pathophysiology and reliably predict treatment outcomes at the individual patient level. For now, it may be assumed that different and possibly age-dependent prototypical forms of depressive disorders exist, which are characterized by specific clinical (psychotic and psychomotor symptoms) and inflammatory markers (higher levels of IL-6 and CRP) and show a differential response to treatment modalities.
- Open Access
- 29 November 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1)
Contemporary in vivo rodent electroconvulsive therapy (ECT) models in translational depression research: a systematic review
Electroconvulsive therapy (ECT) has been established as an efficacious and safe treatment for severe and/or treatment-resistant depression. However, despite decades of research, the exact biological signature of the mechanism of action of ECT has yet to be elucidated. As a translational tool, electroconvulsive stimulation (ECS), the preclinical rodent equivalent of ECT, offers the unique opportunity for further knowledge under controlled laboratory conditions. Here, for the first time, a systematic review following the PRISMA 2020 statement is presented, covering mouse and rat studies investigating the biobehavioral effects of ECS in chronic stress-based depression models. For this purpose, the PubMed and Web of Science databases (period: 01.01.2000 to 05.10.2023) were screened for different key word combinations (search terms: depression, chronic stress, electroconvulsive shock, rats, mice). The search yielded a total of 1455 records. After filtering, a total of 48 studies were included in this review (n = 7 mice, n = 41 rats). Across the reviewed studies, the most common experimental conditions were 4 weeks of chronic unpredictable mild stress (CUMS) in adult male rats treated with bilateral ear clip ECS for 1 week (parameters: bidirectional square wave, 1.5 ms pulse width with 800 mA at 125 Hz, 1.2 sec stimulation duration, 120 mC charge) using no, propofol, or isoflurane anesthesia. The outcome measures were centered around anhedonia-related behaviors and hippocampal protein levels. Summary odds across different behavioral domains revealed antidepressive effects of ECS on anhedonia (14.5), locomotion (6.0), despair (4.5), and anxiety (2.0), accompanied by memory impairments (0.1). Risk of bias assessment suggested considerable risk, primarily due to unreported information on missing data and blinding. Based on our analysis of the evidence, methodological suggestions for future studies were developed. This review will help to further unlock the translational potential of the ECS to generate much needed insights into the molecular correlates of ECT, with special regard to treatment response and prognosis for depression patients.
- 29 November 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1)
Open AccessContemporary in vivo rodent electroconvulsive therapy (ECT) models in translational depression research: a systematic review
Electroconvulsive therapy (ECT) has been established as an efficacious and safe treatment for severe and/or treatment-resistant depression. However, despite decades of research, the exact biological signature of the mechanism of action of ECT has yet to be elucidated. As a translational tool, electroconvulsive stimulation (ECS), the preclinical rodent equivalent of ECT, offers the unique opportunity for further knowledge under controlled laboratory conditions. Here, for the first time, a systematic review following the PRISMA 2020 statement is presented, covering mouse and rat studies investigating the biobehavioral effects of ECS in chronic stress-based depression models. For this purpose, the PubMed and Web of Science databases (period: 01.01.2000 to 05.10.2023) were screened for different key word combinations (search terms: depression, chronic stress, electroconvulsive shock, rats, mice). The search yielded a total of 1455 records. After filtering, a total of 48 studies were included in this review (n = 7 mice, n = 41 rats). Across the reviewed studies, the most common experimental conditions were 4 weeks of chronic unpredictable mild stress (CUMS) in adult male rats treated with bilateral ear clip ECS for 1 week (parameters: bidirectional square wave, 1.5 ms pulse width with 800 mA at 125 Hz, 1.2 sec stimulation duration, 120 mC charge) using no, propofol, or isoflurane anesthesia. The outcome measures were centered around anhedonia-related behaviors and hippocampal protein levels. Summary odds across different behavioral domains revealed antidepressive effects of ECS on anhedonia (14.5), locomotion (6.0), despair (4.5), and anxiety (2.0), accompanied by memory impairments (0.1). Risk of bias assessment suggested considerable risk, primarily due to unreported information on missing data and blinding. Based on our analysis of the evidence, methodological suggestions for future studies were developed. This review will help to further unlock the translational potential of the ECS to generate much needed insights into the molecular correlates of ECT, with special regard to treatment response and prognosis for depression patients.
- Open Access
- 1 March 2025
- Published by Springer Nature in Purinergic Signalling
- Vol. 21 (5) , 1077-1092
Establishment and behavioural characterization of a novel constitutive P2X7 receptor knockout mouse line
The P2X7 receptor is an adenosine triphosphate (ATP)-gated ion channel expressed in different cell types of the brain. Polymorphisms in the P2RX7 gene have repeatedly been associated with psychiatric disorders including major depression. Depression is a stress-related disorder in which a dysregulation of the immune system has attracted increasing attention as a potential disease mechanism. The well-documented role of P2X7 in inflammatory conditions advocates its involvement in immune system dysregulation and depression genesis. However, understanding its exact role requires further research using appropriate animal models. Unfortunately, some of the most widely used P2X7 knockout mouse models are limited in their utility by the continuous expression of certain P2rx7 splice variants or even activation of de novo transcripts. To overcome this limitation, we generated a novel constitutive and complete P2X7 KO mouse line. These KO mice lack all known murine splice variants and protein expression resulting in a loss-of-function as confirmed by calcium imaging and by the inability of P2X7-deficient peritoneal macrophages to mount an appropriate interleukin (IL)-1β response. Comprehensive characterization using a battery of tests assessing locomotion, anxiety- and depression-related as well as social behaviour revealed differences in locomotor and exploratory behaviours. P2X7 KO mice showed slightly increased locomotor activity and reduced anxiety-related behaviour at baseline. Under conditions of chronic stress exposure, genotype-dependent differences largely dissolved while P2X7 deficiency promoted enhanced stress resilience with regard to social behaviour. Taken together, our findings add further evidence for an involvement of the P2X7 in shaping different behavioural responses and their modulation by stressful environments. This novel loss-of-function model will contribute to a better understanding of P2X7 in stress-associated behaviours in basic and translational neuropsychiatric research.
- 1 March 2025
- Published by Springer Nature in Purinergic Signalling
- Vol. 21 (5) , 1077-1092
Open AccessEstablishment and behavioural characterization of a novel constitutive P2X7 receptor knockout mouse line
The P2X7 receptor is an adenosine triphosphate (ATP)-gated ion channel expressed in different cell types of the brain. Polymorphisms in the P2RX7 gene have repeatedly been associated with psychiatric disorders including major depression. Depression is a stress-related disorder in which a dysregulation of the immune system has attracted increasing attention as a potential disease mechanism. The well-documented role of P2X7 in inflammatory conditions advocates its involvement in immune system dysregulation and depression genesis. However, understanding its exact role requires further research using appropriate animal models. Unfortunately, some of the most widely used P2X7 knockout mouse models are limited in their utility by the continuous expression of certain P2rx7 splice variants or even activation of de novo transcripts. To overcome this limitation, we generated a novel constitutive and complete P2X7 KO mouse line. These KO mice lack all known murine splice variants and protein expression resulting in a loss-of-function as confirmed by calcium imaging and by the inability of P2X7-deficient peritoneal macrophages to mount an appropriate interleukin (IL)-1β response. Comprehensive characterization using a battery of tests assessing locomotion, anxiety- and depression-related as well as social behaviour revealed differences in locomotor and exploratory behaviours. P2X7 KO mice showed slightly increased locomotor activity and reduced anxiety-related behaviour at baseline. Under conditions of chronic stress exposure, genotype-dependent differences largely dissolved while P2X7 deficiency promoted enhanced stress resilience with regard to social behaviour. Taken together, our findings add further evidence for an involvement of the P2X7 in shaping different behavioural responses and their modulation by stressful environments. This novel loss-of-function model will contribute to a better understanding of P2X7 in stress-associated behaviours in basic and translational neuropsychiatric research.
- Open Access
Neuropeptide CRH prevents premature differentiation of OPCs following CNS injury and in early postnatal development
Summary: The role of neuropeptides and their receptors in oligodendrocyte progenitor cells (OPCs) has largely been overlooked so far. Here, we describe a new subpopulation of corticotropin-releasing hormone (CRH)-expressing OPCs that aggregate around acute brain injuries and exhibit an elevated capacity to differentiate into myelinating oligodendrocytes (OLs). We found that CRH expression in OPCs is rapidly induced de novo as a transient response within the first 72 hours after injury. As target cells, we identified CRH receptor type 1 (CRHR1)-expressing OPCs which show a decreased differentiation velocity. We demonstrate that CRH/CRHR1 system inactivation increases the speed of OL generation compromising the long-term survival of OLs after acute injury. Furthermore, we prove that a CRH/CRHR1 system deficiency under non-injury conditions leads to increased early postnatal oligodendrogenesis and alterations in adult myelination. Altogether, we show that OPC-derived CRH not only actively influences the injury environment through the interaction with CRHR1-expressing OPCs, but also identify the G-protein coupled receptor CRHR1 as a critical modulator of oligodendrogenesis at early postnatal stages with lasting effects on adult myelination.
Open AccessNeuropeptide CRH prevents premature differentiation of OPCs following CNS injury and in early postnatal development
Summary: The role of neuropeptides and their receptors in oligodendrocyte progenitor cells (OPCs) has largely been overlooked so far. Here, we describe a new subpopulation of corticotropin-releasing hormone (CRH)-expressing OPCs that aggregate around acute brain injuries and exhibit an elevated capacity to differentiate into myelinating oligodendrocytes (OLs). We found that CRH expression in OPCs is rapidly induced de novo as a transient response within the first 72 hours after injury. As target cells, we identified CRH receptor type 1 (CRHR1)-expressing OPCs which show a decreased differentiation velocity. We demonstrate that CRH/CRHR1 system inactivation increases the speed of OL generation compromising the long-term survival of OLs after acute injury. Furthermore, we prove that a CRH/CRHR1 system deficiency under non-injury conditions leads to increased early postnatal oligodendrogenesis and alterations in adult myelination. Altogether, we show that OPC-derived CRH not only actively influences the injury environment through the interaction with CRHR1-expressing OPCs, but also identify the G-protein coupled receptor CRHR1 as a critical modulator of oligodendrogenesis at early postnatal stages with lasting effects on adult myelination.
- Open Access
- 25 September 2024
- Published by Springer Nature in Research Square
Not so different after all: a systematic review of rodent electroconvulsive therapy (ECT) models in translational chronic stress and depression research
Electroconvulsive therapy (ECT) has been established as an efficacious and safe treatment for severe and/or treatment-resistant depression. However, despite decades of research, the exact biological signature of the mechanism of action of ECT has yet to be elucidated. As a translational tool, electroconvulsive stimulation (ECS), the preclinical rodent equivalent of ECT, offers the unique opportunity for further knowledge under controlled laboratory conditions. Here, for the first time, a systematic review following the PRISMA 2020 statement is presented, covering mouse and rat studies investigating the biobehavioral effects of ECS in chronic stress-based depression models. For this purpose, the PubMed and Web of Science databases (period: 01.01.2000 to 05.10.2023) were screened for different key word combinations (search terms: depression, chronic stress, electroconvulsive shock, rats, mice). The search yielded a total of 1067 records. After filtering, a total of 47 studies were included in this review (n = 7 mice, n = 40 rats). Previous studies have used 4 weeks of chronic unpredictable mild stress (CUMS) in adult male rats treated with bilateral ear clip ECS for 1 week (parameters: bidirectional square wave, 1.5 ms pulse width with 800 mA at 125 Hz, 1.2 sec stimulation duration, 120 mC charge) using no, propofol, or isoflurane anesthesia. The outcome measures were centered around anhedonia-related behaviors and hippocampal protein levels. Summary odds across different behavioral domains revealed antidepressive effects of ECS on anhedonia (14.5), locomotion (6.0), despair (4.3), and anxiety (2.0), accompanied by memory impairments (0.1). Risk of bias assessment suggested considerable risk, primarily due to unreported information on missing data and blinding. Based on our analysis of the evidence, methodological suggestions for future studies were developed. This review will help to further unlock the translational potential of the ECS to generate much needed insights into the molecular correlates of ECT, with special regard to treatment response and prognosis for depression patients.
- 25 September 2024
- Published by Springer Nature in Research Square
Open AccessNot so different after all: a systematic review of rodent electroconvulsive therapy (ECT) models in translational chronic stress and depression research
Electroconvulsive therapy (ECT) has been established as an efficacious and safe treatment for severe and/or treatment-resistant depression. However, despite decades of research, the exact biological signature of the mechanism of action of ECT has yet to be elucidated. As a translational tool, electroconvulsive stimulation (ECS), the preclinical rodent equivalent of ECT, offers the unique opportunity for further knowledge under controlled laboratory conditions. Here, for the first time, a systematic review following the PRISMA 2020 statement is presented, covering mouse and rat studies investigating the biobehavioral effects of ECS in chronic stress-based depression models. For this purpose, the PubMed and Web of Science databases (period: 01.01.2000 to 05.10.2023) were screened for different key word combinations (search terms: depression, chronic stress, electroconvulsive shock, rats, mice). The search yielded a total of 1067 records. After filtering, a total of 47 studies were included in this review (n = 7 mice, n = 40 rats). Previous studies have used 4 weeks of chronic unpredictable mild stress (CUMS) in adult male rats treated with bilateral ear clip ECS for 1 week (parameters: bidirectional square wave, 1.5 ms pulse width with 800 mA at 125 Hz, 1.2 sec stimulation duration, 120 mC charge) using no, propofol, or isoflurane anesthesia. The outcome measures were centered around anhedonia-related behaviors and hippocampal protein levels. Summary odds across different behavioral domains revealed antidepressive effects of ECS on anhedonia (14.5), locomotion (6.0), despair (4.3), and anxiety (2.0), accompanied by memory impairments (0.1). Risk of bias assessment suggested considerable risk, primarily due to unreported information on missing data and blinding. Based on our analysis of the evidence, methodological suggestions for future studies were developed. This review will help to further unlock the translational potential of the ECS to generate much needed insights into the molecular correlates of ECT, with special regard to treatment response and prognosis for depression patients.
- Open Access
- 30 August 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (3) , 673-684
Multiomics and blood-based biomarkers of electroconvulsive therapy in severe and treatment-resistant depression: study protocol of the DetECT study
Electroconvulsive therapy (ECT) is commonly used to treat treatment-resistant depression (TRD). However, our knowledge of the ECT-induced molecular mechanisms causing clinical improvement is limited. To address this issue, we developed the single-center, prospective observational DetECT study (“Multimodal Biomarkers of ECT in TRD”; registered 18/07/2022, www.clinicalTrials.gov, NCT05463562). Its objective is to identify molecular, psychological, socioeconomic, and clinical biomarkers of ECT response in TRD. We aim to recruit n = 134 patients in 3 years. Over the course of 12 biweekly ECT sessions (± 7 weeks), participant blood is collected before and 1 h after the first and seventh ECT and within 1 week after the twelfth session. In pilot subjects (first n = 10), additional blood draws are performed 3 and 6 h after the first ECT session to determine the optimal post-ECT blood draw interval. In blood samples, multiomic analyses are performed focusing on genotyping, epigenetics, RNA sequencing, neuron-derived exosomes, purines, and immunometabolics. To determine clinical response and side effects, participants are asked weekly to complete four standardized self-rating questionnaires on depressive and somatic symptoms. Additionally, clinician ratings are obtained three times (weeks 1, 4, and 7) within structured clinical interviews. Medical and sociodemographic data are extracted from patient records. The multimodal data collected are used to perform the conventional statistics as well as mixed linear modeling to identify clusters that link biobehavioural measures to ECT response. The DetECT study can provide important insight into the complex mechanisms of ECT in TRD and a step toward biologically informed and data-driven-based ECT biomarkers.
- 30 August 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (3) , 673-684
Open AccessMultiomics and blood-based biomarkers of electroconvulsive therapy in severe and treatment-resistant depression: study protocol of the DetECT study
Electroconvulsive therapy (ECT) is commonly used to treat treatment-resistant depression (TRD). However, our knowledge of the ECT-induced molecular mechanisms causing clinical improvement is limited. To address this issue, we developed the single-center, prospective observational DetECT study (“Multimodal Biomarkers of ECT in TRD”; registered 18/07/2022, www.clinicalTrials.gov, NCT05463562). Its objective is to identify molecular, psychological, socioeconomic, and clinical biomarkers of ECT response in TRD. We aim to recruit n = 134 patients in 3 years. Over the course of 12 biweekly ECT sessions (± 7 weeks), participant blood is collected before and 1 h after the first and seventh ECT and within 1 week after the twelfth session. In pilot subjects (first n = 10), additional blood draws are performed 3 and 6 h after the first ECT session to determine the optimal post-ECT blood draw interval. In blood samples, multiomic analyses are performed focusing on genotyping, epigenetics, RNA sequencing, neuron-derived exosomes, purines, and immunometabolics. To determine clinical response and side effects, participants are asked weekly to complete four standardized self-rating questionnaires on depressive and somatic symptoms. Additionally, clinician ratings are obtained three times (weeks 1, 4, and 7) within structured clinical interviews. Medical and sociodemographic data are extracted from patient records. The multimodal data collected are used to perform the conventional statistics as well as mixed linear modeling to identify clusters that link biobehavioural measures to ECT response. The DetECT study can provide important insight into the complex mechanisms of ECT in TRD and a step toward biologically informed and data-driven-based ECT biomarkers.
- 2 December 2022
- Published by Elsevier in Neuropharmacology
- Vol. 224, 109366
The P2X7 receptor in mood disorders: Emerging target in immunopsychiatry, from bench to bedside
- 2 December 2022
- Published by Elsevier in Neuropharmacology
- Vol. 224, 109366
The P2X7 receptor in mood disorders: Emerging target in immunopsychiatry, from bench to bedside
- Open Access
- 14 September 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (1) , 329-340
Introducing a depression-like syndrome for translational neuropsychiatry: a plea for taxonomical validity and improved comparability between humans and mice
Depressive disorders are the most burdensome psychiatric disorders worldwide. Although huge efforts have been made to advance treatment, outcomes remain unsatisfactory. Many factors contribute to this gridlock including suboptimal animal models. Especially limited study comparability and replicability due to imprecise terminology concerning depressive-like states are major problems. To overcome these issues, new approaches are needed. Here, we introduce a taxonomical concept for modelling depression in laboratory mice, which we call depression-like syndrome (DLS). It hinges on growing evidence suggesting that mice possess advanced socioemotional abilities and can display non-random symptom patterns indicative of an evolutionary conserved disorder-like phenotype. The DLS approach uses a combined heuristic method based on clinical depression criteria and the Research Domain Criteria to provide a biobehavioural reference syndrome for preclinical rodent models of depression. The DLS criteria are based on available, species-specific evidence and are as follows: (I) minimum duration of phenotype, (II) significant sociofunctional impairment, (III) core biological features, (IV) necessary depressive-like symptoms. To assess DLS presence and severity, we have designed an algorithm to ensure statistical and biological relevance of findings. The algorithm uses a minimum combined threshold for statistical significance and effect size (p value ≤ 0.05 plus moderate effect size) for each DLS criterion. Taken together, the DLS is a novel, biologically founded, and species-specific minimum threshold approach. Its long-term objective is to gradually develop into an inter-model validation standard and microframework to improve phenotyping methodology in translational research.
- 14 September 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (1) , 329-340
Open AccessIntroducing a depression-like syndrome for translational neuropsychiatry: a plea for taxonomical validity and improved comparability between humans and mice
Depressive disorders are the most burdensome psychiatric disorders worldwide. Although huge efforts have been made to advance treatment, outcomes remain unsatisfactory. Many factors contribute to this gridlock including suboptimal animal models. Especially limited study comparability and replicability due to imprecise terminology concerning depressive-like states are major problems. To overcome these issues, new approaches are needed. Here, we introduce a taxonomical concept for modelling depression in laboratory mice, which we call depression-like syndrome (DLS). It hinges on growing evidence suggesting that mice possess advanced socioemotional abilities and can display non-random symptom patterns indicative of an evolutionary conserved disorder-like phenotype. The DLS approach uses a combined heuristic method based on clinical depression criteria and the Research Domain Criteria to provide a biobehavioural reference syndrome for preclinical rodent models of depression. The DLS criteria are based on available, species-specific evidence and are as follows: (I) minimum duration of phenotype, (II) significant sociofunctional impairment, (III) core biological features, (IV) necessary depressive-like symptoms. To assess DLS presence and severity, we have designed an algorithm to ensure statistical and biological relevance of findings. The algorithm uses a minimum combined threshold for statistical significance and effect size (p value ≤ 0.05 plus moderate effect size) for each DLS criterion. Taken together, the DLS is a novel, biologically founded, and species-specific minimum threshold approach. Its long-term objective is to gradually develop into an inter-model validation standard and microframework to improve phenotyping methodology in translational research.
- Open Access
- 12 July 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 915058
Combined Fainting and Psychogenic Non-epileptic Seizures as Significant Therapy Hurdles in Blood-Injury-Injection Phobia: A Mini-Review and Case Report
Background: Anxiety disorders are the most frequent mental disorders. Among the different subtypes, specific phobias are the commonest. Due to the ongoing SARS-CoV-19 pandemic, blood-injury-injection phobia (BII) has gained wider attention in the context of large-scale vaccination campaigns and public health. In this BII phobia mini-review and case report, we describe the successful treatment of a severe BII phobia case with combined fainting and psychogenic non-epileptic seizures (PNES) and demonstrate the role of specialized outpatient care.Case Report: The patient was a 28-year-old woman. She suffered from intense fear and recurrent fainting with regard to needles, injections, injuries, and at the sight of blood since early childhood. Medical history revealed infrequent events suggestive of PNES following panic attacks after sustained exposure to phobic stimuli. Family history was positive for circulation problems and BII fears. Psychopathological evaluation confirmed BII phobia symptoms and diagnosis was made according to the DSM-5. The Multidimensional Blood/Injury Phobia Inventory short version (MBPI-K) revealed severe manifestation of the disease. Neurological examination was ordinary. Repeated electroencephalography detected no epileptic pattern. Cranial magnetic resonance imaging showed normal morphology. Treatment was carried out by a seasoned, multidisciplinary team. Cognitive behavior therapy and exposure were performed. Modification of standard treatment protocol was necessary due to hurdles posed by recurrent fainting and a severe panic-triggered dissociative PNES during in vivo exposure. Modification was implemented by limiting in vivo exposure intensity to moderate anxiety levels. In addition to applied muscle tension and ventilation techniques, increased psychoeducation, cognitive restructuring, and distress tolerance skills (e.g., ice pack, verbal self-instructions) were used to strengthen the patient's situational control during in vivo exposure. A total of 15 sessions were performed. Therapy success was proven by 83% reduction in MBPI-K rating, SARS-CoV-19 vaccination, and a blood draw without psychological assistance, fainting, or seizure.Conclusion: Taken together, this case demonstrates the potential of and need for specialized outpatient care and individualized treatment for severe BII phobia patients in order to provide them the perspective to have necessary medical procedures done and get vaccinated.
- 12 July 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 915058
Open AccessCombined Fainting and Psychogenic Non-epileptic Seizures as Significant Therapy Hurdles in Blood-Injury-Injection Phobia: A Mini-Review and Case Report
Background: Anxiety disorders are the most frequent mental disorders. Among the different subtypes, specific phobias are the commonest. Due to the ongoing SARS-CoV-19 pandemic, blood-injury-injection phobia (BII) has gained wider attention in the context of large-scale vaccination campaigns and public health. In this BII phobia mini-review and case report, we describe the successful treatment of a severe BII phobia case with combined fainting and psychogenic non-epileptic seizures (PNES) and demonstrate the role of specialized outpatient care.Case Report: The patient was a 28-year-old woman. She suffered from intense fear and recurrent fainting with regard to needles, injections, injuries, and at the sight of blood since early childhood. Medical history revealed infrequent events suggestive of PNES following panic attacks after sustained exposure to phobic stimuli. Family history was positive for circulation problems and BII fears. Psychopathological evaluation confirmed BII phobia symptoms and diagnosis was made according to the DSM-5. The Multidimensional Blood/Injury Phobia Inventory short version (MBPI-K) revealed severe manifestation of the disease. Neurological examination was ordinary. Repeated electroencephalography detected no epileptic pattern. Cranial magnetic resonance imaging showed normal morphology. Treatment was carried out by a seasoned, multidisciplinary team. Cognitive behavior therapy and exposure were performed. Modification of standard treatment protocol was necessary due to hurdles posed by recurrent fainting and a severe panic-triggered dissociative PNES during in vivo exposure. Modification was implemented by limiting in vivo exposure intensity to moderate anxiety levels. In addition to applied muscle tension and ventilation techniques, increased psychoeducation, cognitive restructuring, and distress tolerance skills (e.g., ice pack, verbal self-instructions) were used to strengthen the patient's situational control during in vivo exposure. A total of 15 sessions were performed. Therapy success was proven by 83% reduction in MBPI-K rating, SARS-CoV-19 vaccination, and a blood draw without psychological assistance, fainting, or seizure.Conclusion: Taken together, this case demonstrates the potential of and need for specialized outpatient care and individualized treatment for severe BII phobia patients in order to provide them the perspective to have necessary medical procedures done and get vaccinated.